Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.97), $0.18 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $15 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
• Ciena (CIEN) Tops Q3 EPS by 39c, Offers Guidance
• John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance